Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

ClinicalTrials.gov ID: NCT01143077

Public ClinicalTrials.gov record NCT01143077. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 10:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, 6-week, Open-Label, Study Evaluating The Safety, Tolerability, and Efficacy of Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.

Study identification

NCT ID
NCT01143077
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Enrollment
244 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2010
Primary completion
Apr 30, 2011
Completion
Apr 30, 2011
Last update posted
Apr 16, 2013

2010 – 2011

United States locations

U.S. sites
27
U.S. states
12
U.S. cities
24
Facility City State ZIP Site status
K and S Professional Research Services Little Rock Arkansas 72201
Synergy Clinical Research of Escondido Escondido California 92025
Collaborative Neuroscience Network, Inc. Garden Grove California 92845
Pacific Research Partners, LLC Oakland California 94612
California Clinical Trials Paramount California 90723
Pasadena Research Institute Pasadena California 91107
California Neuropsychopharmacology Clinical Research Institute (CNRI), LLC Pico Rivera California 90660
California Neuropsychopharmacology Clinical Research Institute (CNRI) San Diego California 92102
University of California San Diego Medical Center San Diego California 92103-8218
Collaborative Neuroscience Network, South Bay Torrance California 90502
Western Affiliated Research Institute Denver Colorado 80204
Comprehensive NeuroScience, Inc. Atlanta Georgia 30328
Medical College of Georgia Augusta Georgia 30912
University of Illinois at Chicago Chicago Illinois 60612
Lake Charles Clinical Trials, LLC Lake Charles Louisiana 70601
Saint Charles Psychiatric Associates/Midwest Research Group Saint Charles Missouri 63301
Neurobehavioral Research, Inc. Cedarhurst New York 11516
The Zucker Hillside Hospital Glen Oaks New York 11004
Duke University Dept. of Psychiatry Durham North Carolina 27710
Wake Forest University Health Sciences Winston-Salem North Carolina 27157
CRI Worldwide - Kirkbride Center Philadelphia Pennsylvania 19131
FutureSearch Clinical Trials, LP Austin Texas 78731
FutureSearch Trials of Dallas Dallas Texas 75231
Pillar Clinical Research, LLC Dallas Texas 75243
University of Texas Southwestern Medical Center Dallas Texas 75390-8828
Wharton Research Center Houston Texas 77488
University of Utah Hospitals and Clinics Salt Lake City Utah 84132

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01143077, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 16, 2013 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01143077 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →